Front Barnett Associates’s AbbVie ABBV Stock Holding History

Front Barnett Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$953K	Sell	6,394 -516	-7%	-$75.8K	0.11%	63
2023 Q2	$931K	Sell	6,910 -45	-0.6%	-$6.6K	0.11%	67
2023 Q1	$1.11M	Sell	6,955 -6	-0.1%	-$917	0.13%	64
2022 Q4	$1.13M	Hold	6,961	–	–	0.14%	65
2022 Q3	$934K	Sell	6,961 -9,108	-57%	-$1.31M	0.12%	70
2022 Q2	$2.46M	Buy	16,069 +9,433	+142%	+$1.44M	0.3%	48
2022 Q1	$1.08M	Buy	6,636 +6	+0.1%	+$872	0.11%	68
2021 Q4	$898K	Sell	6,630 -100	-1%	-$11.8K	0.08%	75
2021 Q3	$726K	Sell	6,730 -466	-6%	-$53.2K	0.07%	80
2021 Q2	$811K	Hold	7,196	–	–	0.08%	77
2021 Q1	$779K	Hold	7,196	–	–	0.09%	72
2020 Q4	$771K	Hold	7,196	–	–	0.09%	70
2020 Q3	$630K	Hold	7,196	–	–	0.09%	70
2020 Q2	$707K	Sell	7,196 -2	-0%	-$176	0.11%	68
2020 Q1	$548K	Buy	7,198 +1,335	+23%	+$114K	0.1%	71
2019 Q4	$519K	Sell	5,863 -2	-0%	-$166	0.08%	85
2019 Q3	$444K	Sell	5,865 -145	-2%	-$9.94K	0.07%	87
2019 Q2	$437K	Sell	6,010 -1,092	-15%	-$85.8K	0.07%	89
2019 Q1	$572K	Sell	7,102 -71	-1%	-$5.81K	0.09%	84
2018 Q4	$661K	Sell	7,173 -260	-3%	-$22.9K	0.12%	75
2018 Q3	$703K	Sell	7,433 -105	-1%	-$9.96K	0.11%	79
2018 Q2	$698K	Sell	7,538 -660	-8%	-$64.5K	0.12%	77
2018 Q1	$776K	Sell	8,198 -90	-1%	-$9.89K	0.13%	76
2017 Q4	$802K	Sell	8,288 -275	-3%	-$25.9K	0.13%	78
2017 Q3	$761K	Hold	8,563	–	–	0.13%	77
2017 Q2	$621K	Sell	8,563 -100	-1%	-$6.72K	0.11%	79
2017 Q1	$564K	Hold	8,663	–	–	0.1%	81
2016 Q4	$542K	Hold	8,663	–	–	0.1%	83
2016 Q3	$546K	Hold	8,663	–	–	0.1%	81
2016 Q2	$536K	Sell	8,663 -313	-3%	-$19.1K	0.11%	80
2016 Q1	$513K	Buy	8,976 +400	+5%	+$22.3K	0.1%	82
2015 Q4	$508K	Hold	8,576	–	–	0.1%	82
2015 Q3	$467K	Buy	8,576 +700	+9%	+$45.6K	0.1%	80
2015 Q2	$529K	Hold	7,876	–	–	0.1%	77
2015 Q1	$461K	Hold	7,876	–	–	0.08%	78
2014 Q4	$515K	Buy	7,876 +661	+9%	+$41.7K	0.1%	77
2014 Q3	$417K	Hold	7,215	–	–	0.08%	82
2014 Q2	$407K	Sell	7,215 -25	-0.3%	-$1.31K	0.08%	80
2014 Q1	$372K	Sell	7,240 -680	-9%	-$34.4K	0.07%	83
2013 Q4	$418K	Sell	7,920 -1,122	-12%	-$55.1K	0.08%	77
2013 Q3	$404K	Buy	9,042 +10	+0.1%	+$443	0.09%	78
2013 Q2	$373K	Buy	+9,032	New	+$395K	0.09%	78

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Front Barnett Associates's ABBV Position: Q3 2023 in Review

Front Barnett Associates reduced its AbbVie (ABBV) stake by 7.5% in Q3 2023, selling an estimated $75.8K and leaving 6,394 shares worth $953K. The position accounts for 0.11% of the portfolio, ranked #63.

Front Barnett Associates first reported a position in ABBV in Q2 2013 and has held it in 42 quarters since. The position peaked at $2.46M in Q2 2022. 3,109 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

Front Barnett Associates held 6,394 shares of AbbVie worth $953K as of Q3 2023.
Front Barnett Associates sold 516 AbbVie shares in Q3 2023, an estimated $75.8K.
AbbVie made up 0.11% of Front Barnett Associates's portfolio in Q3 2023, its #63 holding.
Front Barnett Associates first reported a position in AbbVie in Q2 2013 and has held it in 42 quarters since.
Front Barnett Associates's AbbVie position peaked at $2.46M in Q2 2022.
3,109 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Front Barnett Associates's 13F filing for Q3 2023, filed 13 Nov 2023.